Phase I trial of vandetanib and oral etoposide (VP-16) for recurrent malignant gliomas (MG).

被引：1
|
作者：
Brickhouse, A. [1 ]
Vredenburgh, J. J. [1 ]
Gururangan, S. [1 ]
Reardon, D. A. [1 ]
Desjardins, A. [1 ]
Peters, K. [1 ]
Herndon, J. E. [1 ]
Norfleet, J. [1 ]
Marcello, J. [1 ]
Friedman, H. S. [1 ]
机构：
[1] Duke Univ, Med Ctr, Durham, NC USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2010年 / 28卷 / 15期
关键词：
D O I：
10.1200/jco.2010.28.15_suppl.2038
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
2038
引用
收藏
页数：1
相关论文
共 50 条
  • [31] An early phase II study of etoposide (VP-16) in advanced gastric cancer
    Yamao, T
    Shimada, Y
    Ohtsu, A
    Hosokawa, K
    Shirao, K
    Kondo, H
    Fukuda, H
    Saito, D
    Yoshida, S
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 1996, 26 (01) : 36 - 41
  • [32] A MULTICENTER PHASE-II TRIAL OF CISPLATIN AND ORAL ETOPOSIDE (VP-16) IN INOPERABLE NON-SMALL-CELL LUNG-CANCER
    SPLINTER, T
    KOK, T
    KHO, S
    LAMERIS, H
    TENKATE, F
    DALESIO, O
    DOLMAN, B
    PALMEN, F
    BOUVY, J
    BURGHOUTS, J
    SIMONIS, F
    HARPER, P
    RANKIN, E
    VANREIJSWOUD, I
    VANHOOGENHUIJZE, J
    SEMINARS IN ONCOLOGY, 1986, 13 (03) : 97 - 103
  • [33] PHASE-I STUDY OF VP-16 (ETOPOSIDE) AND AMSACRINE (AMSA) IN THE TREATMENT OF REFRACTORY ACUTE-LEUKEMIA
    LETENDRE, L
    HINEMANN, V
    HOAGLAND, HC
    KOVACH, JS
    MEDICAL AND PEDIATRIC ONCOLOGY, 1985, 13 (04): : 232 - 234
  • [34] A PHASE-I TRIAL OF CONTINUOUS INFUSION VP16-213 (ETOPOSIDE)
    AISNER, J
    VANECHO, DA
    WHITACRE, M
    WIERNIK, PH
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 1982, 7 (2-3) : 157 - 160
  • [35] A phase II study of temozolomide and oral VP-16 for adults with recurrent glioma - Final results.
    Korones, D. N.
    Benita-Weiss, M.
    Coyle, T.
    Bushunow, P.
    Mechtler, L.
    Friedman, H. S.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 74S - 74S
  • [36] Plasma pharmacokinetics of etoposide (VP-16) after i.v. administration to children
    Eksborg, S
    Söderhäll, S
    Frostvik-Stolt, M
    Lindberg, A
    Liliemark, E
    ANTI-CANCER DRUGS, 2000, 11 (04) : 237 - 241
  • [37] CISPLATIN AND ETOPOSIDE (VP-16) AS A SINGLE REGIMEN FOR SMALL CELL LUNG-CANCER - A PHASE-II TRIAL
    BONI, C
    COCCONI, G
    BISAGNI, G
    CECI, G
    PERACCHIA, G
    CANCER, 1989, 63 (04) : 638 - 642
  • [38] PHASE-I TRIAL OF HIGH-DOSE ARA-C AND VP-16
    POWELL, BL
    MUSS, HB
    CAPIZZI, RL
    CAPONERA, ME
    WHITE, DR
    ZEKAN, PJ
    ATKINS, JN
    JACKSON, DV
    RICHARDS, F
    CRAIG, JB
    SPURR, CL
    PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, 1986, 27 : 175 - 175
  • [39] TOLERABLE TOXICITY AND HIGH REMISSION RATES IN NSCLC - A PHASE-II TRIAL WITH ETOPOSIDE (VP-16) AND CISPLATIN (CDDP)
    WILKE, H
    ACHTERRATH, W
    BOELSCKEI, P
    FINK, U
    GUNZER, U
    MEYER, P
    BLUT, 1985, 51 (03): : 196 - 197
  • [40] Lenalidomide and irinotecan in adults with recurrent malignant gliomas: Phase I results of the phase I/II trial
    Puduvalli, Vinay K.
    Groves, Morris D.
    Gilbert, Mark R.
    Hess, Kenneth R.
    Kang, Sanghee
    Ictech, Sandra
    Conrad, Charles A.
    Loghin, Monica Elena
    De Groot, John Frederick
    Levin, Victor A.
    Yung, W. K. Alfred
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
12345